SIC
GILD icon

Shoker Investment Counsel’s Gilead Sciences GILD Stock Holding History

Shoker Investment Counsel’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.93M Sell
21,050
-658
-3% -$92.1K 0.87% 31
2025
Q4 		$2.66M Buy
21,708
+66
+0.3% +$8.02K 0.78% 39
2025
Q3 		$2.4M Sell
21,642
-338
-2% -$38.4K 0.71% 43
2025
Q2 		$2.44M Sell
21,980
-858
-4% -$91.3K 0.76% 42
2025
Q1 		$2.56M Buy
22,838
+189
+0.8% +$19.5K 0.86% 40
2024
Q4 		$2.09M Buy
22,649
+345
+2% +$31.1K 0.71% 48
2024
Q3 		$1.87M Sell
22,304
-89
-0.4% -$6.79K 0.63% 51
2024
Q2 		$1.54M Buy
22,393
+3,092
+16% +$206K 0.54% 51
2024
Q1 		$1.41M Buy
19,301
+493
+3% +$37.9K 0.5% 48
2023
Q4 		$1.52M Buy
18,808
+854
+5% +$66.5K 0.59% 48
2023
Q3 		$1.35M Sell
17,954
-47
-0.3% -$3.62K 0.58% 46
2023
Q2 		$1.39M Buy
18,001
+150
+0.8% +$12K 0.58% 45
2023
Q1 		$1.48M Sell
17,851
-282
-2% -$23.4K 0.65% 48
2022
Q4 		$1.56M Buy
18,133
+696
+4% +$55.1K 0.7% 47
2022
Q3 		$1.07M Buy
17,437
+2,120
+14% +$134K 0.56% 47
2022
Q2 		$946K Buy
15,317
+2,070
+16% +$128K 0.5% 49
2022
Q1 		$787K Buy
13,247
+374
+3% +$23.9K 0.39% 54
2021
Q4 		$934K Buy
12,873
+36
+0.3% +$2.48K 0.43% 53
2021
Q3 		$896K Buy
12,837
+1,415
+12% +$99.4K 0.45% 55
2021
Q2 		$786K Buy
11,422
+628
+6% +$41.9K 0.39% 55
2021
Q1 		$697K Buy
10,794
+1,953
+22% +$126K 0.37% 59
2020
Q4 		$515K Sell
8,841
-3,551
-29% -$214K 0.29% 62
2020
Q3 		$783K Buy
12,392
+790
+7% +$54.8K 0.51% 52
2020
Q2 		$892K Buy
11,602
+220
+2% +$16.9K 0.62% 48
2020
Q1 		$850K Buy
11,382
+2,064
+22% +$143K 0.72% 46
2019
Q4 		$605K Buy
9,318
+838
+10% +$54.6K 0.4% 57
2019
Q3 		$537K Buy
8,480
+244
+3% +$15.9K 0.39% 59
2019
Q2 		$556K Buy
8,236
+1,357
+20% +$89.3K 0.41% 59
2019
Q1 		$447K Buy
6,879
+1,745
+34% +$116K 0.33% 64
2018
Q4 		$321K Sell
5,134
-733
-12% -$51.2K 0.27% 76
2018
Q3 		$453K Buy
5,867
+405
+7% +$30.6K 0.33% 67
2018
Q2 		$386K Buy
5,462
+191
+4% +$13.5K 0.29% 73
2018
Q1 		$397K Buy
5,271
+547
+12% +$43.5K 0.3% 75
2017
Q4 		$338K Sell
4,724
-345
-7% -$26.2K 0.24% 85
2017
Q3 		$410K Buy
5,069
+729
+17% +$55.7K 0.31% 73
2017
Q2 		$307K Buy
4,340
+294
+7% +$19.6K 0.24% 81
2017
Q1 		$274K Sell
4,046
-148
-4% -$10.4K 0.23% 86
2016
Q4 		$300K Buy
4,194
+1,312
+46% +$97.5K 0.25% 84
2016
Q3 		$228K Buy
+2,882
New +$234K 0.19% 94

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Shoker Investment Counsel's GILD Position: Q1 2026 in Review

Shoker Investment Counsel reduced its Gilead Sciences (GILD) stake by 3% in Q1 2026, selling an estimated $92.1K and leaving 21,050 shares worth $2.93M. The position accounts for 0.87% of the portfolio, ranked #31.

Shoker Investment Counsel first reported a position in GILD in Q3 2016 and has held it in 39 quarters since. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Shoker Investment Counsel held 21,050 shares of Gilead Sciences worth $2.93M as of Q1 2026.
  • Shoker Investment Counsel sold 658 Gilead Sciences shares in Q1 2026, an estimated $92.1K.
  • Gilead Sciences made up 0.87% of Shoker Investment Counsel's portfolio in Q1 2026, its #31 holding.
  • Shoker Investment Counsel first reported a position in Gilead Sciences in Q3 2016 and has held it in 39 quarters since.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Shoker Investment Counsel's 13F filing for Q1 2026, filed 11 May 2026.